Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ELCC 2019 | Overcoming the challenges of precision medicine in lung cancer

Giorgio Vittorio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses challenges in the use of personalized medicines for lung cancers, which have greatly improved overall survival. Prof. Scagliotti explains that the plasticity of tumor cells enables them to acquire resistance to targeted immunotherapy, and how this may be addressed in the future using molecules targeting this resistance mechanism. This video was recorded at the European Lung Cancer Congress (ELCC), held in Geneva, Switzerland.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.